Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) SF 424 (R&R) Other Project Information ? Project Summary The Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU), current NIAID CRMS site 60338, is a collaboration between the Chiang Mai University-Research Institute for Health Sciences (CMU- RIHES) in Chiang Mai, Thailand, and the Thai Red Cross AIDS Research Centre (TRC-ARC) in Bangkok, Thailand.
The specific aims of this application are 1) to renew the THAI CTU as a Clinical Trials Unit to provide scientific, administrative expertise, and infrastructure to conduct clinical studies developed by the four NIH HIV/AIDS Clinical Trials Networks: HIV/AIDS Adult Therapeutics, HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics, HIV Prevention, and HIV Vaccines; and 2) to participate in the development of clinical trials and provide four Clinical Research Sites (CRS) to conduct clinical trials proposed by the four Networks. This CTU renewal involves a change of THAI CTU Principal Investigators from Suwat Chariyalertsak and Kiat Ruxrungtham to ?Khuanchai Supparatpinyo and Kiat Ruxrungtham. The THAI CTU and its four CRSs will contribute scientifically to the Networks and recruit HIV+ and HIV- participants to clinical studies according to HIV/AIDS research priorities: 1) HIV/AIDS adult therapeutics: 1) interventions to reduce HIV reservoirs; 2) novel and durable interventions targeting HIV treatment; 3) treatment and prevention of drug-sensitive and drug-resistant tuberculosis; 4) treatment and prevention of HIV-related, non-infectious co-morbidities; and 5) studied strategies to cure hepatitis B virus infection in people with and without HIV. High national incidence of viral hepatitis and endemicity of carriage facilitates research on HBV and HCV infections, particularly for cure of hepatitis B. 2) HIV/AIDS maternal, adolescent and pediatric therapeutics: 1) optimization of antiretroviral treatment for these populations; 2) interventions for ART-free remission; 3) treatment and prevention of tuberculosis; 4) treatment and prevention of HIV-related co-morbidities; and 5) treatment and prevention of co-infections. 3) HIV prevention: 1) evaluation of long-acting antiretroviral agents and delivery systems for pre- exposure prophylaxis; 2) evaluation of multipurpose prevention technologies for HIV, pregnancy, sexually transmitted infections, and opioid dependence; 3) evaluation of broadly neutralizing antibodies for pre-exposure prophylaxis; and 4) integrated strategies for HIV prevention. 4) HIV vaccines: 1) evaluation of passive immunization to reduce HIV acquisition in adults; 2) investigation of vaccination of infants; 3) evaluation of immunological, microbiological, and diagnostic technologies for TB vaccination; and 4) research on epidemiological, behavioral, and social sciences for optimization of outcomes of HIV vaccination.

Public Health Relevance

Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) SF 424 (R&R) Other Project Information ? Project Narrative The Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) is a collaboration between the Chiang Mai University-Research Institute for Health Sciences (CMU-RIHES) in Chiang Mai, Thailand, and the Thai Red Cross AIDS Research Centre (TRC-ARC) in Bangkok, Thailand. The renewed THAI CTU and its four CRSs will participate in developing and conducting clinical trials proposed by the four NIH HIV/AIDS Clinical Trials Networks: HIV/AIDS adult therapeutics; HIV/AIDS maternal, adolescent and pediatric therapeutics; HIV prevention; and HIV vaccines. The collaboration between the NIH HIV/AIDS Clinical Trials Networks and their affiliated CTUs, including the THAI CTU, will lead to development of innovative and effective measures for HIV treatment and prevention, and ultimately to HIV cure and an end to the global HIV epidemic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI069399-15
Application #
10054211
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Germuga, Donna E
Project Start
2007-03-15
Project End
2027-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
15
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Chiang Mai University
Department
Type
DUNS #
City
Chiang Mai
State
Country
Thailand
Zip Code
50200
Robertson, K; Oladeji, B; Jiang, H et al. (2018) HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction. Clin Infect Dis :
Salazar-Austin, N; Kulich, M; Chingono, A et al. (2018) Age-Related Differences in Socio-demographic and Behavioral Determinants of HIV Testing and Counseling in HPTN 043/NIMH Project Accept. AIDS Behav 22:569-579
Shivakoti, Rupak; Ewald, Erin R; Gupte, Nikhil et al. (2018) Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. Clin Nutr :
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
Palumbo, Philip J; Fogel, Jessica M; Hudelson, Sarah E et al. (2018) HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr 77:484-491
Greer, Amy E; Ou, San-San; Wilson, Ethan et al. (2017) Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr 76:388-393
Celum, Connie; Hong, Ting; Cent, Anne et al. (2017) Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J Infect Dis 215:907-910
Currier, Judith S; Britto, Paula; Hoffman, Risa M et al. (2017) Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ? 400 cells/mm3. PLoS One 12:e0176009
Carballo-Diéguez, Alex; Balán, Ivan C; Brown 3rd, William et al. (2017) High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS One 12:e0181607
Cranston, Ross D; Lama, Javier R; Richardson, Barbra A et al. (2017) MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clin Infect Dis 64:614-620

Showing the most recent 10 out of 41 publications